Explore Gilead Sciences, Inc.'s 8-K report detailing significant corporate changes and events affecting investors as of August 7, 2025. Stay informed on GILD's latest developments.
Discover Amgen's impressive Q2 2025 results with $9.179B revenue and $1.432B net income. Learn why it's a buy for investors!
Explore Vertex Pharmaceuticals' impressive Q2 2025 financial performance, featuring $1B net income and rising revenues. A recommended BUY for investors!
Explore Amgen Inc.'s latest 8-K filing detailing common stock and senior notes. Key insights on financing and corporate strategy included.
Discover Gilead Sciences, Inc.'s latest 8-K filing revealing significant shareholder updates as of July 30, 2025. Stay informed on GILD stock and financial transparency.
Explore Vertex Pharmaceuticals Inc.'s recent 8-K filing detailing significant events on August 4, 2025. Key insights on common stock and financial disclosures included.
Explore Moderna's Q2 2025 financial report highlighting a net loss of $825M, cash decline, and deferred revenue growth. Investment recommendation: Hold.
Explore Regeneron Pharmaceuticals' Q2 2025 financial performance, highlighting $1.39B net income, key products, and ongoing challenges. Investors advised to hold.
Discover the latest 8-K filing by Moderna, Inc. (MRNA) on August 1, 2025. Learn about significant events impacting shareholders and stock performance.
Explore Regeneron Pharmaceuticals' 8-K filing detailing significant corporate events on August 1, 2025. Stay informed on shareholder impacts and market changes.
Explore Illumina, Inc.'s 8-K filing from July 31, 2025, including vital company info, stock data, and structured reporting insights.
Explore Biogen Inc.'s Q2 2025 financial highlights, including revenue growth, R&D investments, and emerging challenges. A must-read for investors focused on biopharmaceutical trends.